Introgen's Q2 finances hold steady - Bizjournals.com
Introgen's Q2 finances hold steadyBizjournals.com, NC - Aug 6, 2007… to move our lead product Advexin closer to market for head and neck cancer and the inherited cancer, Li-Fraumeni Syndrome," says CEO David Nance. …
Read full story